Status:

COMPLETED

Clinical Study of Genakumab for Injection in Patients With Acute Gout

Lead Sponsor:

Changchun GeneScience Pharmaceutical Co., Ltd.

Collaborating Sponsors:

Huashan Hospital

Hainan General Hospital

Conditions:

Acute Gout

Eligibility:

All Genders

18-65 years

Phase:

PHASE1

PHASE2

Brief Summary

To evaluate the safety and tolerability of single subcutaneous injection of Genakumab for Injection in patients with acute gout

Detailed Description

Phase Ib: single arm, open lable, single dose, dose escalation,design. There are 3 dose groups with 10 participant s in each group. Phase II: randomized, double-blind, active control design.There are...

Eligibility Criteria

Inclusion

  • Inclusion Criteria:
  • Male or female, 18 years ≤ age ≤65 years
  • Meeting the American College of Rheumatology (ACR) 2015 preliminary criteria for the classification of acute arthritis of primary gout
  • Contraindication, intolerance or lack of efficacy for NSAIDs and/or colchicine
  • Body mass index of less than or equal to 45 kg/m2
  • Onset of current acute gout flare within 5 days prior to study entry
  • Baseline pain intensity ≥ 50 mm on the 0-100 mm visual analog scale (VAS)
  • History of gout flare prior to study entry
  • Exclusion criteria:
  • evidence/suspicion of infectious/septic arthritis, or other acute inflammatory arthritis
  • Presence of severe renal function impairment
  • Use of specified pain relief medications or biologics ( corticosteroids, narcotics, paracetamol/acetominophen, ibuprofen, colchicine, IL-blocker, and tumor necrosis factor inhibitor) within specified periods prior to study entry
  • Live vaccinations within 3 months prior to randomization
  • Requirement for administration of antibiotics against latent tuberculosis (TB)
  • Any active or recurrent bacterial, fungal, or viral infection
  • QTc\>450ms for male, QTc\>470ms for female

Exclusion

    Key Trial Info

    Start Date :

    May 22 2021

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    June 9 2022

    Estimated Enrollment :

    121 Patients enrolled

    Trial Details

    Trial ID

    NCT05328531

    Start Date

    May 22 2021

    End Date

    June 9 2022

    Last Update

    February 27 2025

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Shanghai Huashan Hospital affiliated to Fudan University

    Shanghai, Shanghai Municipality, China, 310000

    Clinical Study of Genakumab for Injection in Patients With Acute Gout | DecenTrialz